Bioequivalence study of a sustained release fixed dose combination capsule containing esomeprazole and domperidone in healthy subjects

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 5, 2007, Pages 274-277

  Agarwal, Sangita ^a   Gowda, Kadajji Veeran ^a   Mandal, Uttam ^a   Ghosh, Debotri ^a   Bose, Anirbandeep ^a   Sarkar, Amlan Kanti ^a   Chattaraj, Tapas Kumar ^b   Pal, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

CAS 326602 80 6; CAS 57808 66 9; Domperidone, bioequivalence, fixed dose combination, pharmacokinetics; Esomeprazole, bioequivalence, fixed dose combination, pharmacokinetics; Proton pump inhibitors; Raciper D

Indexed keywords

DOMPERIDONE; DOMPERIDONE PLUS ESOMEPRAZOLE; ESOMEPRAZOLE; RACIPER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION;

EID: 34250023157     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296618     Document Type: Article

References (15)

1. Fass R. Epidemiology and pathophysiology of symptomatic gastro esophageal reflux disease. Am J Gastroenterol. 2003;98 (Suppl):S2-S7.
2. Damiano A, Siddique R, Xu X, Johanson J, Sloan S. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastro esophageal reflux disease treated with rabeprazole. Dig Dis Sci. 2003;44:657-662.
3. Spechler SJ. Epidemiology and natural history of gastro esophageal reflux disease. Digestion. 1992;51 (Suppl 1):24-29.
4. Rai A, Orlando R. Gastro esophageal reflux disease. Curr Opin Gastroenterol. 1998;14:326-333.
5. Thomson AB, Chiba N, Armstrong D, Tougas G, Hunt RH. The Second Canadian Gastro esophageal Reflux Disease Consensus: Moving forward to new concepts. Can J Gastroenterol. 1998;12(8):551-556.
6. Orlando RC. The pathogenesis of gastroesophageal reflux disease: The relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol. 1997;92 (Suppl4):3s-7s.
7. Andersson T Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Clin Pharmacokinet. 1996; 31:9-28.
8. Albelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000;28:966-972.
9. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf W. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001; 40(6):411-426.
10. Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut. 1996;38(5):649-654.
11. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs. 1982;24:360-400.
12. Talpes S, Knoerzer D, Huber R, Pfaffenberger B. Esomeprazole MUPS 40 mg tablets and esomeprazole MUPS 40 mg tablets encapsulated in hard gelatine are bioequivalent. Int J Clin Pharmacol Ther. 2005;43(1):51-56.
13. Min-Shu Wu, GAO-Ling, Xio-Hui CAI, Guang-Ji Wang, Determination of Domperidone in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers. Acta Pharmacol Sin. 2002;23(3):585-588.
14. Shah VP, Midha KK, Sighe S. Analytical method validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokin. 1992;16:249-255.
15. th ed. Hamilton: Hamilton Press; 1992. p. 588.